Bispecific antibodies in the treatment of multiple myeloma

• by Anup Joseph Devasia, Ajai Chari, Guido Lancman

• September 12, 2024

A single next generation sequencing assay for detection of driver mutations, rearrangements and copy number abnormalities in plasma cell dyscrasias

• by Cecilia Bonolo de Campos, Daniela Trujillo, James Smadbeck, Mariano Arribas, Hongwei Tang, Neeraj Sharma, Gregory J. Ahmann, Shaji K. Kumar, A. Keith Stewart, Rafael Fonseca, P. Leif Bergsagel, Yan W. Asmann, Linda B. Baughn, Esteban Braggio

• March 28, 2026

Patient-reported outcomes after idecabtagene vicleucel vs. ciltacabtagene autoleucel CAR-T for multiple myeloma

• by Laura B. Oswald, Xiaoyin Li, Lisa M. Gudenkauf, Gabe De Avila, David Scheiber-Camoretti, Brent J. Small, Brian D. Gonzalez, Aasha I. Hoogland, Oanh Nguyen, Yvelise Rodriguez, Sylvia L. Crowder, Nathan H. Parker, Tiffany L. Carson, Christine E. Vinci, Rachid C. Baz, Kenneth H. Shain, Brandon Blue, Ariel Grajales-Cruz, Kristy Matte, Brandon Kale, David Kaldas, Fabiana Perna, Melissa Alsina, Ciara L. Freeman, Omar Castaneda Puglianini, Taiga Nishihori, Hien Liu, Frederick L. Locke, Heather S. L. Jim, Lauren C. Peres, Doris K. Hansen

• May 11, 2026

Dana-Farber Team Develops Open-Access Predictive Tool to Improve Monitoring of Smoldering Multiple Myeloma

The tool, called PANGEA-SMM, outperforms existing predictive tools by more accurately determining when smoldering multiple myeloma is progressing and requires treatment. The free online tool can be used immediately to monitor patients.

• by

• March 24, 2026

• 5 min